Pharma BD Deal Intelligence

Valeant Pharmaceuticals International, Inc. / Medicis Pharmaceutical Corporation

2012 · Acquisition/Merger · $2.6B · Complete

Announcement Sentiment

Positive

Valeant acquired Medicis at $44/share cash for $2.6B (39% premium). Combined dermatology/aesthetics franchise pro forma 2012 US revenue >$1.7B. Identified $225M cost synergies within 6 months.

Did it work? Outcome assessment

Strategic verdict

Failed to Achieve

Financial impact

Impaired/Written Down

Pipeline outcome

Mixed

Assessment window: 5yr post-close.

Key facts

Announced Sep 03, 2012
Closed Dec 11, 2012
Deal value $2.6B
Deal type Acquisition/Merger
Therapeutic area Dermatology and aesthetics
Indications Dermatology and aesthetics
Key assets Solodyn, Restylane, Perlane, Ziana, Dysport, Zyclara
Mechanism Multiple (dermatologic, aesthetic injectables)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals